Liquid biopsy-guided kidney-sparing management in upper tract urothelial carcinoma: from preoperative risk stratification to perioperative surveillance
Difei Yu, Jiarun Tang, Yu Zhang, Ke Hu, Jing Qing, Jiamo Zhang · 2026
Read Liquid biopsy-guided kidney-sparing management in upper tract urothelial carcinoma: from preoperative risk stratification to perioperative surveillance by Difei Yu, Jiarun Tang, Yu Zhang, Ke Hu, Jing Qing, Jiamo Zhang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13268921.txt.
Description
Difei Yu and co-authors review in 2026 how liquid biopsy tests might guide kidney-sparing care for cancer of the upper urinary tract. Removing the whole kidney and ureter is the standard for high-risk disease, but it sacrifices kidney function. Choosing patients safely for lesser surgery is hard because scans and scope biopsies describe shape better than tumor biology.
Urine-based tests, covering gene methylation, mutations, RNA panels, and proteins, look most ready for detecting cancer and sorting patients before surgery. Tumor DNA in blood, by contrast, tracked hidden aggressive disease and leftover cancer after operations. The authors stress that these tests should add a decision layer on top of imaging and pathology, not replace them, and that outcome trials are the next step.
Catalog record
| CREATOR | Difei Yu, Jiarun Tang, Yu Zhang, Ke Hu, Jing Qing, Jiamo Zhang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 73 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |